Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Double Blind, Parallel Group, Two Arm, Comparative, Multicenter, Clinical Study to Compare Efficacy and Safety of Oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India Against Innovator Sitagliptin 100 mg in Patients With Uncontrolled Type-2 Diabetes Mellitus (T2DM)

NCT04801199 is registered in ClinicalTrials.gov with Cadila Pharnmaceuticals as lead sponsor.

NCT NCT04801199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04801199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Double Blind, Parallel Group, Two Arm, Comparative, Multicenter, Clinical Study to Compare Efficacy and Safety of Oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India Against Innovator Sitagliptin 100 mg in Patients With Uncontrolled Type-2 Diabetes Mellitus (T2DM)
Lead sponsor
Cadila Pharnmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
January 26, 2020
Completion date
February 11, 2021
Enrollment
355 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

uncontrolled type 2 diabetes mellitus